Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.

TitleElevated serum periostin levels in patients with bone metastases from breast but not lung cancer.
Publication TypeJournal Article
Year of Publication2003
AuthorsSasaki H, Yu C-Y, Dai M, Tam C, Loda M, Auclair D, Chen LBo, Elias A
JournalBreast Cancer Res Treat
Volume77
Issue3
Pagination245-52
Date Published2003 Feb
ISSN0167-6806
KeywordsAdult, Biomarkers, Tumor, Bone Neoplasms, Breast Neoplasms, Carcinoma, Small Cell, Cell Adhesion Molecules, Female, Humans, In Situ Hybridization, Luminescent Measurements, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Polymerase Chain Reaction, Predictive Value of Tests
Abstract

Periostin is a recently identified gene that is preferentially expressed in periosteum, indicating a potential role in bone formation and maintenance of structure. We independently identified and isolated periostin from cancer tissue, using the palindromic PCR-driven cDNA Differential Display technique. For the present work, we developed a novel sandwich chemiluminescence assay to detect serum periostin level using newly developed monoclonal and polyclonal antibodies. We investigated serum periostin levels in breast cancer and small cell lung cancer patients, especially in patients with bone metastasis. The study included 58 breast cancer and 44 small cell lung cancer patients. Serum periostin levels were elevated in breast cancer patients presenting with bone metastases (92.0 +/- 28.6 ng/ml) compared to similar breast cancer patients without evidence of bone metastasis (55.0 +/- 16.6 ng/ml, p = 0.04). No correlation was found between the serum periostin level and any other prognostic factors, such as clinical stage and lymph node metastasis in breast cancer. Serum periostin levels thus appear to serve as a marker of bone metastasis from breast cancer. In contrast, serum periostin levels were similar in samples from patients with small cell lung cancer who did or did not have bone metastasis. However, increasing T-stage and N-stage of patients with small cell lung cancer were correlated with higher periostin levels (T4, 126.5 +/- 29.7 ng/ml v.s. T2, 64.9 +/- 16.1 ng/ml, p = 0.03; and T4 v.s. T1, 36.3+/- 7.5 ng/ml, p = 0.01; N3, 108.7 +/- 17.3 ng/ml v.s. N2, 49.7+/- 10.9 ng/ml, p = 0.01). Periostin has a substantial homology with the insect cell adhesion molecule, fasciclin I. Thus, expression of periostin may facilitate tumor cell adhesion to the bone surface. In fact, we found by in situ RNA hybridization, that the periostin gene was highly expressed in the stromal cells immediately surrounding the tumor, but not within the breast cancer cells themselves.

DOI10.1023/a:1021899904332
Alternate JournalBreast Cancer Res Treat
PubMed ID12602924
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700